Country for PR: United States
Contributor: PR Newswire New York
Wednesday, April 08 2020 - 11:00
AsiaNet
HOYA/PENTAX Medical Issues Statement Regarding U.S. Department of Justice Settlement
MONTVALE, N.J. and TOKYO, April 8, 2020 /PRNewswire-AsiaNet/ --

HOYA Corporation and a subsidiary through PENTAX Medical division, Pentax of 
America, Inc. (collectively, "PENTAX" or "the Company"), today finalized a 
Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) 
on issues related to the timely filing of Medical Device Reports (MDRs) for 
PENTAX Medical's duodenoscopes and providing updated Instructions for Use 
(IFUs) for several PENTAX Medical products. PENTAX first disclosed the DOJ 
investigation in June 2015. 

Logo - https://mma.prnewswire.com/media/1076915/Pentax_Logo.jpg 

In the DPA, PENTAX acknowledged that it did not timely submit two required MDRs 
to the U.S. Food and Drug Administration (FDA) for events in the US between 
July 2013 and December 2014. In addition, PENTAX acknowledged that it failed to 
send FDA approved IFUs for four types of endoscopes from April 2014 until 
September 2015. PENTAX agreed to: pay a fine and forfeiture totaling $43 
million; undertake new steps to enhance its compliance policies and procedures; 
and regularly make certain certifications that PENTAX is meeting the 
requirements of the DPA.

"PENTAX deeply regrets that it did not timely file the MDRs identified in the 
DPA, as well as the failure to send the approved IFUs to customers. We accept 
full responsibility for these failures," said David Woods, President of Pentax 
of America, Inc. 

The DPA does not allege any direct harm to patients as a result of the 
disclosure failures or failure to send IFUs, and PENTAX acknowledged that it 
failed to comply with the federal reporting requirements. The DPA does not 
impact the availability of PENTAX Medical products and services worldwide. 

"PENTAX Medical is committed to the highest standards of ethical behavior and 
we are confident we can fulfill each of the obligations under this DPA to the 
fullest extent necessary," said Gerry Bottero, Global President, PENTAX 
Medical. 

The full text of the DPA will be available on the PENTAX Medical website 
(https://www.pentaxmedical.com/pentax/en/99/1/Compliance-and-Ethics ). 

At PENTAX Medical, we have an unwavering commitment to our customers and their 
patients to provide safe, high-quality products and services that offer true 
value. To that end, we develop products and services that enable our customers 
to improve clinical outcomes, reduce the cost of healthcare, and enhance the 
experience they deliver to patients. This approach is demonstrated in how we 
develop clinically relevant endoscopy products, advance cleaning procedures, 
continuously improve our internal procedures, and empower our customers through 
expert training and education programs. While we always strive to deliver on 
our promises, how we achieve those results is equally as important. 

About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company's mission is to improve 
the standard of patient care and quality of healthcare delivery by providing 
the best endoscopic products and services with a focus on QUALITY, CLINICALLY 
RELEVANT INNOVATION, and SIMPLICITY.
Through providing endoscopic imaging devices and solutions to the global 
medical community and with its headquartered in Japan, PENTAX Medical has a 
worldwide focus and a strong presence with R&D, regional sales, service, and 
in-country facilities in multiple regions around the globe.
PENTAX Medical's Triple Aim program strives to deliver on the commitment to 
support its customers and their healthcare organization's wider objectives 
through a transparent partnership and by providing the highest quality 
solutions to help them reach their goals. Enabling customers to improve patient 
outcomes by offering evidenced based solutions across the continuum of care, 
dedicated to their needs. From screening through to therapy with full 
scalabilities. Ensuring values by supporting the customers to improve their 
efficiency and minimize their healthcare costs. Enriching patient and 
provider's experience by empowering every member of the care team to achieve 
optimal outcomes through products, education and support. For more information, 
please visit: www.pentaxmedical.com. For more information, please visit 
https://www.pentaxmedical.com.

About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and 
med-tech company and a leading supplier of innovative high-tech and medical 
products. HOYA's divisions and business units research and develop products 
utilized in the healthcare and information technology fields. 
In the healthcare field, we provide medical device products such as eyeglasses, 
medical endoscopes, contact and intraocular lenses, orthopedic implants, 
surgical/therapeutic devices and medical device reprocessing and disinfection 
solutions.  In the information technology field, we provide products such as 
optical lenses, photomasks and blanks used in the manufacturing process for 
semiconductor and LCD/OLED devices, text to speech, human resources and other 
software solutions and critical components for the mass memory and cloud 
storage industries. With over 150 offices and subsidiaries worldwide, HOYA 
currently employs a multinational workforce of 37,000 people. For more 
information, please visit http://www.hoya.com

Mariano Franco 
1 (905) 580-7725 
mariano.franco@pentaxmedical.com 

SOURCE  PENTAX Medical
Translations

Japanese